The COVID-19 pandemic has shown that the cost of underinvesting in resilient systems for the development, production, and distribution of health technologies is too high.
This paper introduces biologics, describes opportunities in the sector, and provides insights about the processes for manufacturing them. It then identifies the diverse pathways that countries have used in recent years to develop bio-manufacturing capacity. Finally, it looks to the future to identify the government policies and technology solutions that will enable more countries to join global value chains and to produce these life-saving treatments more safely, quickly, and cost-effectively – to the benefit of patients everywhere.
Click here for the full story.